Apricus CEO to Discuss Company''s Drug Portfolio, Including Its Topical Cream for Erectile Dysfunction, Vitaros(R), LIVE on iHeart (Clear Channel) Business Talk Radio DFW 1190AM on Sept. 25, 2014
Interview to Air at 7:30am EDT / 4:30am PDT / 6:30am CDT on the Traders Network Radio Show, Hosted by Michael Yorba
(firmenpresse) - DALLAS, TX and SAN DIEGO, CA -- (Marketwired) -- 09/24/14 -- Richard Pascoe, CEO of biopharmaceutical developer, Apricus Biosciences, Inc. (NASDAQ: APRI) will be interviewed live tomorrow on iHeart (Clear Channel) Business Talk Radio. Mr. Pascoe will discuss the Company''s prescription erectile dysfunction treatment Vitaros®, which was launched commercially in the UK, Germany and Sweden this year and is expected to roll out in other European countries later this year and in 2015. He will also review Apricus'' development portfolio, which includes drug candidate RayVa™ targeted to treat the circulatory condition, Raynaud''s phenomenon secondary to scleroderma. Raynaud''s affects the extremities in an estimated 3 - 5% of the U.S. population. Femprox®, Apricus'' third drug candidate, is targeted for the treatment of female sexual interest / arousal disorder.
September 25, 2014
7:30am EDT | 4:30am PDT | 6:30am CDT (U.S.)
Clear Channel - iHeart
KFXR
The Traders Network
Michael Yorba
Clear Channel''s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. .
Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has produced and hosted "The Traders Network Show" broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am - 7:30am and 2pm - 3pm CT, Monday-Friday. Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It''s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more... shift your thinking and join us as we deliver "tomorrow''s ideas today" on Clear Channel''s The Traders Network Show.
Apricus Biosciences, Inc. is a pharmaceutical company developing fast-acting, topical treatments that address large patient populations that struggle with unmet medical needs. Vitaros® is the Company''s rapid-onset (5-15 minutes) topical cream treatment for erectile dysfunction. Vitaros is approved in Europe and Canada and is being commercialized by Apricus'' marketing partners, which include Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Other product candidates are RayVa™ a potential first-in-class topical treatment for Raynaud''s phenomenon secondary to scleroderma, and Femprox®, for the treatment of female sexual interest / arousal disorder.
*PR and Editorial Services by
Image Available:
Image Available:
Matthew Bird
1-800-PublicRelations.com, Inc.
(917) 409-8211
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.09.2014 - 12:35 Uhr
Sprache: Deutsch
News-ID 1305058
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
DALLAS, TX and SAN DIEGO, CA
Phone:
Kategorie:
Personal Care & Fitness
Anmerkungen:
Diese Pressemitteilung wurde bisher 366 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apricus CEO to Discuss Company''s Drug Portfolio, Including Its Topical Cream for Erectile Dysfunction, Vitaros(R), LIVE on iHeart (Clear Channel) Business Talk Radio DFW 1190AM on Sept. 25, 2014
"
steht unter der journalistisch-redaktionellen Verantwortung von
The Trader Network Show (Clear Channel DFW 1190AM KFXR) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
